FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

스택 라이브러리

Neuro Performance Stack

Cognitive Enhancementintermediate

81

상호작용

81
Share
펩타이드

3

일 평균 mcg

1,150

수준

intermediate

추가됨

May 17, 2026

개요

The Neuro Performance Stack extends the classic Russian Brain Stack (Semax + Selank) with BPC-157, adding a gut-brain axis component and systemic healing support to the core cognitive and anxiolytic effects. This combination is particularly popular with high-performers dealing with both cognitive demands and physical stress. Semax and Selank provide the core cognitive effects: BDNF upregulation, focus, memory, and anxiolytic stability (see Russian Brain Stack for detailed mechanisms). BPC-157 adds a dimension that neither cognitive peptide addresses — the gut-brain connection. The gut-brain axis is increasingly recognized as a bidirectional communication system where GI health directly impacts cognitive function, mood, and stress resilience. BPC-157 heals the gut mucosal lining, reduces intestinal inflammation, and supports neurotransmitter production in the enteric nervous system. Users with gut dysfunction often find that cognitive peptides underperform until the gut component is addressed. Beyond gut-brain axis effects, BPC-157 has direct central nervous system activity. It modulates dopaminergic signaling, has demonstrated neuroprotective effects in animal models of brain injury, and supports peripheral nerve regeneration. In the context of this stack, BPC-157 provides a supportive background of neural tissue health that complements Semax''s acute BDNF upregulation. This stack is particularly well-suited for practitioners, executives, athletes, and high-performers who face both cognitive demands and physical stress — situations where the body''s healing capacity and cognitive performance are both taxed simultaneously.

용량 프로토콜

Semax

Every day· intranasal

Semax에 대한 자세한 내용 →

600 mcg

1회 용량당

Selank

Every day· intranasal

Selank에 대한 자세한 내용 →

300 mcg

1회 용량당

BPC-157

Every day· subcutaneous

BPC-157에 대한 자세한 내용 →

250 mcg

1회 용량당

목표 및 증거

Cognitive performanceAnxiety reductionGut-brain healthNeural protectionStress resilience
증거 등급:동물 연구

경고

  • BPC-157 was removed from the FDA Category 2 list (April 2026) but remains under PCAC review (July 23, 2026) — not legal to compound yet.

Comments

Sign in to join the discussion

주의: 이 스택은 커뮤니티에서 제출된 것이며 연구용으로만 사용됩니다. Peptide Contacts는 제출된 스택의 안전성이나 효능을 검증하지 않습니다. 펩타이드 프로토콜을 사용하기 전에 항상 자격이 있는 의료 전문가와 상의하세요.